Standout Papers

Empagliflozin, Cardiovascular Outcomes, and Mortalit... 2006 2026 2012 2019 7.8k
  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
    Bernard Zinman, Christoph Wanner et al. New England Journal of Medicine
  2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016)
    Steven P. Marso, Gilbert H. Daniels et al. New England Journal of Medicine
  3. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2008)
    David M. Nathan, John B. Buse et al. Diabetes Care
  4. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
    Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine
  5. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine
  6. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (2017)
    Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine
  7. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006)
    Hertzel C. Gerstein, Salim Yusuf et al. The Lancet
  8. Impaired Fasting Glucose and Impaired Glucose Tolerance (2007)
    David M. Nathan, Mayer B. Davidson et al. Diabetes Care
  9. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2006)
    David M. Nathan, John B. Buse et al. Diabetes Care
  10. Liraglutide and Renal Outcomes in Type 2 Diabetes (2017)
    Johannes F.E. Mann, David D. Ørsted et al. New England Journal of Medicine
  11. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
    Julio Rosenstock, Vlado Perkovic et al. JAMA
  12. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) (2009)
    Bernard Zinman, John Gerich et al. Diabetes Care
  13. Are Metabolically Healthy Overweight and Obesity Benign Conditions? (2013)
    Caroline K. Kramer, Bernard Zinman et al. Annals of Internal Medicine
  14. Diabetic Retinopathy and Diabetic Macular Edema (2003)
    Thomas A. Ciulla, A. G. Amador et al. Diabetes Care
  15. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008)
    David M. Nathan, John B. Buse et al. Diabetologia
  16. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
    Silvio E. Inzucchi, Bernard Zinman et al. Diabetes Care
  17. Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes (2009)
    Michael Mauer, Bernard Zinman et al. New England Journal of Medicine
  18. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis (2017)
    M. Angelyn Bethel, Rishi Patel et al. The Lancet Diabetes & Endocrinology
  19. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (2017)
    Steven P. Marso, Darren K. McGuire et al. New England Journal of Medicine
  20. Type 1 Diabetes Mellitus and Cardiovascular Disease (2014)
    Sarah D. de Ferranti, Ian H. de Boer et al. Circulation
  21. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes (2019)
    Julio Rosenstock, Steven E. Kahn et al. JAMA
  22. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019)
    Subodh Verma, C. David Mazer et al. Circulation
  23. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
    Christoph Wanner, John M. Lachin et al. Circulation
  24. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality (2015)
    Trevor J. Orchard, David M. Nathan et al. JAMA
  25. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial (2017)
    David Z.I. Cherney, Bernard Zinman et al. The Lancet Diabetes & Endocrinology
  26. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  27. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (2019)
    Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology
  28. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials (2018)
    Julio Rosenstock, Jan Marquard et al. Diabetes Care
  29. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2019)
    David Fitchett, Silvio E. Inzucchi et al. Circulation
  30. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  31. Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers (2022)
    Caroline Holm Nørgaard, Sarah Friedrich et al. Alzheimer s & Dementia Translational Research & Clinical Interventions
  32. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal

Immediate Impact

2 from Science/Nature 187 standout
Sub-graph 1 of 14

Citing Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
95 intermediate papers

Works of Bernard Zinman being referenced

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
2023 Standout
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
2022 Standout
and 66 more

Author Peers

Author Last Decade Papers Cites
Bernard Zinman 43046 17578 18193 643 61.2k
David R. Matthews 42881 16026 17935 266 73.6k
Steven M. Haffner 32314 10874 10990 517 60.5k
William C. Knowler 21517 8108 10313 516 56.0k
Hertzel C. Gerstein 25805 7930 8604 496 49.6k
Markku Laakso 22794 11434 15999 667 56.6k
Ele Ferrannini 28308 13056 14917 523 50.0k
Gerald M. Reaven 29768 10168 13376 663 58.0k
Melanie J. Davies 30305 9575 10447 994 54.5k
Naveed Sattar 22026 12405 8966 1.2k 70.7k
John B. Buse 54476 19976 25946 595 76.1k

All Works

Loading papers...

Rankless by CCL
2026